NFKB1 and acute myeloid leukemia: The abnormal expression of GSK-3 and the activation of canonical NF-κB pathway may be implicated in AML, and the non-canonical NF-κB pathway activated through a GSK-3-independent mechanism may play a key role in the development of drug resistance.